Press Releases

AIkido Pharma Inc. today reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug. With respect to manufacturing process, the Company reported the successful development of a new means for the scale

Newomics Inc., a biotechnology company commercializing mass spectrometry solutions for molecular detection, and Bruker Corporation, with differentiated high-value life science research and diagnostics solutions, today announced collaborations on a novel LC-MS platform for drug discovery in the Pharma/Biopharma industry as well as research institutions. The two companies agreed on co-marketing Newomics’s Microflow-nanospray Electrospray Ionization (MnESI) product line with Bruk

The Mid-Atlantic Technology, Research & Innovation Center (MATRIC®) today announced it will establish the Center of Excellence (CoE) for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities

Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region. Avance Clinical's CEO Yvonne Lungershausen said: "We continue to offer a hybrid working environment for our team however, they are increasingly wanting more in-office face-to-face time with colleagues and clients - while still having the flexibility of working remo

TFF Pharmaceuticals, Inc.and Catalent today announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals’ patented Thin Film Freezing (TFF) technology. Under the agreement, Catalent will provide its scale-up expertise and manufacturing capabilities to TFF Pharmaceuticals as its preferred development and manufacturing partner, and Catalent will be able to

Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class therapies for patients with chronic kidney disease (CKD), today announced its formation made possible through initial seed financing from DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), and Catalys Pacific. Pathalys launches with a novel clinical-stage asset, upacicalcet, that was acquired through a license granted by EA Pharma for exclusive righ

German independent research institute BioMed X announces today the start of its new research project ‘Advanced Biomarker Detection for Pharmacological Monitoring in the Brain’ (BDB) in collaboration with Boehringer Ingelheim. The objective of the research group ‘BDB’ is to develop a continuous monitoring biosensor for direct detection of small molecule biomarkers in rodent brain tissue to support the development of innovative treatment approaches in precision psychiatr

Affinivax, Inc.  and Astellas Pharma Inc.  today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae. In conjunction with the rights reacquisition by Affinivax, ASP3772 will be renamed AFX3772. Closing of the transaction is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act, which is expected in March or April of 2022. Under

Ramm Pharma Corp. On February 22, 2022, the Company announced that, for reasons set out in its news release of February 22, 2022, the filing of its annual audited financial statements for the year ended October 31, 2021, the accompanying management's discussion and analysis and the related CEO and CFO certifications (collectively, the "Annual Filings") would not be filed by the prescribed deadline of February 28, 2022 (the “Deadline”). The Company was not g

Vallon Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Meenu Karson to its Board of Directors. “We are excited to welcome Ms. Karson to our Board of Directors. Over the course of her career, she has led a successful IPO, raised significant capital to advance clinical development programs, and has played